Mission BioCapital

Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.

Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.

AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.

GraphWear Technologies Inc. is a Philadelphia-based company that develops an advanced nanotechnology sensing platform capable of non-invasively monitoring vital body metrics in real-time through sweat, breath, and saliva. The company specializes in wearable patch sensors that measure lactic acid and glucose levels, offering solutions for dehydration monitoring and glucose detection. These devices are particularly beneficial for professional sports teams, college athletics, and amateur athletes, as they help optimize performance and prevent dehydration. Founded in 2015, GraphWear aims to revolutionize healthcare by providing continuous monitoring of hydration and sugar levels without the need for blood or urine samples, using innovative technology to ensure a hassle-free health tracking experience.

Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.

Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.

Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.

Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.

Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.

Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.

Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.

Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. It specializes in developing and commercializing silk biomaterial technologies aimed at improving vaccine delivery and storage. The company has created the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapies, and the MATRIX formulation and drying platform, which enhances the stability of vaccines, therapeutics, and diagnostic products. By utilizing a silk-derived protein, Vaxess enables vaccines to be stored and transported without refrigeration, thereby reducing distribution costs and increasing access to essential healthcare products globally.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.

Tangible Science, LLC specializes in the development of innovative products aimed at enhancing the comfort of contact lens users, particularly those suffering from dry eye conditions. Founded in 2011 and based in Redwood City, California, the company has created a polymer coating technology that provides a bio-compatible and highly hydrated surface for contact lenses. This technology helps maintain the natural tear film, significantly reducing discomfort associated with lens wear. Tangible Science's product offerings include contact lens coatings, cleaners, rejuvenators, and a line of disposable lenses, all designed to improve the overall experience for patients, eye care professionals, and contact lens manufacturers.

Operator of a biotechnology company intended to develop medicine to reverse cancer cell immortality. The company's medicine specializes in inhibiting cancer cell immortality by undergoing immortalization process, leaving healthy cells intact, enabling patients to get cured of diseases such as cancer.

Invenio Imaging, Inc. is a privately held company founded in 2012 and based in Santa Clara, California. The company specializes in developing advanced technology for non-destructive microscopic analysis of the molecular composition of tissues and materials. Its primary product is a multi-modal coherent Raman scattering microscope, which is designed for both research and high-value medical applications. This innovative imaging system facilitates intraoperative histology by providing high-resolution images that allow researchers to examine tissue specimens from multiple surgical sites. Invenio Imaging's technology is underpinned by research from Prof. Sunney Xie at Harvard University and has received funding from the National Science Foundation and the National Institutes of Health's Small Business Innovation Research programs.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. The company integrates automation, machine learning, and genomics to enhance its platform, which aids in optimizing microbial strains and improving the efficiency of production processes. By leveraging big data and artificial intelligence, Zymergen collaborates with clients to engineer novel molecules from microbes, thereby advancing product development. Founded in 2013 and headquartered in Emeryville, California, Zymergen also has offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, enabling it to serve a global clientele effectively.

GraphWear Technologies Inc. is a Philadelphia-based company that develops an advanced nanotechnology sensing platform capable of non-invasively monitoring vital body metrics in real-time through sweat, breath, and saliva. The company specializes in wearable patch sensors that measure lactic acid and glucose levels, offering solutions for dehydration monitoring and glucose detection. These devices are particularly beneficial for professional sports teams, college athletics, and amateur athletes, as they help optimize performance and prevent dehydration. Founded in 2015, GraphWear aims to revolutionize healthcare by providing continuous monitoring of hydration and sugar levels without the need for blood or urine samples, using innovative technology to ensure a hassle-free health tracking experience.

Bolt Threads Inc. is a materials company based in Emeryville, California, founded in 2009. The company specializes in the manufacture of innovative fibers and fabrics, including its signature biofabricated silk fibers known as Microsilk. Utilizing proprietary technology and advanced bioengineering concepts, Bolt Threads develops next-generation performance fibers and fabrics aimed at enhancing quality, performance, and design in various sectors, including apparel, footwear, and beauty. The company focuses on sustainable practices by transforming textile waste into new products, positioning itself as a leader in environmentally responsible textile production.

Redwood Bioscience specializes in precision protein-chemical engineering to create optimized biotherapeutics. The company employs site-specific modification technology, which addresses the challenges of conjugating biologics with synthetic molecules, resulting in homogeneous hybrid biotherapeutics. These hybrid drugs combine the specificity and extended half-life of biologics with the potency of synthetic peptides and small molecules. By utilizing modified carrier scaffolds, Redwood develops peptide therapeutics aimed at enhancing serum half-lives and antibody-drug conjugates that exhibit improved potency and reduced toxicity. Additionally, the company is expanding the chemical space of protein drugs by creating heterofunctional products with unique architectures. Redwood collaborates with partners to enhance the value of existing programs and to jointly develop innovative compounds while also pursuing its own internal biotherapeutic programs.